Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Wimolnut Manheng"'
Autor:
Asma Dilawari, Mirat Shah, Gwynn Ison, Haley Gittleman, Mallorie H. Fiero, Ankit Shah, Salaheldin S. Hamed, Junshan Qiu, Jingyu Yu, Wimolnut Manheng, Tiffany K. Ricks, Rajan Pragani, Arulvathani Arudchandran, Paresma Patel, Shadia Zaman, Arpita Roy, Shyam Kalavar, Soma Ghosh, William F. Pierce, Nam Atiqur. Rahman, Shenghui Tang, Bronwyn D. Mixter, Paul G. Kluetz, Richard Pazdur, Laleh Amiri-Kordestani
Publikováno v:
Clinical Cancer Research.
On November 14, 2022, the U.S. Food and Drug Administration (FDA) granted accelerated approval to mirvetuximab soravtansine-gynx for treatment of adult patients with folate receptor-α (FRα)-positive, platinum-resistant epithelial ovarian, fallopian
Autor:
Shawn F. Harris, Wimolnut Manheng, Kimber L. White, Travis Gulledge, Kristen Ryan, Dori R. Germolec, Michelle J. Hooth, Victor J. Johnson, Rachel P. Frawley, Keith R. Shockley
Publikováno v:
Journal of Applied Toxicology. 42:392-408
Ionic liquids (ILs) are synthetic solvents used as replacements for volatile organic solvents. Human exposure occurs through dermal or oral routes. In rodents, several ILs were reported to induce dermal toxicity, irritation, and sensitization. Due to
Autor:
Matthew D. Stout, Matthew Buccellato, Helen Cunny, David E. Malarkey, Kristine L. Witt, Shawn F. Harris, Dawn Fallacara, Rachel P. Frawley, Irene Inok Surh, Dori R. Germolec, Wimolnut Manheng, Kimber L. White, Greg Travlos, Grace E. Kissling, Daven N. Jackson-Humbles, Keith R. Shockley, Scott S. Auerbach
Publikováno v:
Toxicology
2-Methoxy-4-nitroaniline (MNA), an intermediate in the synthesis of azo dyes used in textiles and paints, is structurally similar to carcinogenic anilines. Human exposure occurs primarily in the occupational setting through handling of dye dust, and
Autor:
Todd R. Palmby, Jeannette Dinin, Laleh Amiri-Kordestani, Pengfei Song, Xiao Hong Chen, Kirsten B. Goldberg, Anamitro Banerjee, Fang Li, Reena Philip, William F. Pierce, Jingyu Yu, Shenghui Tang, Gideon M. Blumenthal, Sharon L. Kelly, Anuradha Ramamoorthy, Amna Ibrahim, Rosane Charlab, Julia A. Beaver, Gwynn Ison, Wimolnut Manheng, Vadryn Pierre, Soma Ghosh, Lynn J. Howie, Richard Pazdur, Lijun Zhang, Rajeshwari Sridhara, Eunice Y. Lee, Okponanabofa Eradiri, Hisani N. Horne, Paul G. Kluetz, Kumar G. Janoria, Kaushalkumar Dave
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 24(17)
The FDA approved niraparib, a poly(ADP-ribose) polymerase (PARP) inhibitor, on March 27, 2017, for maintenance treatment of patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response to platinum-based